Obagi Medical Products, Inc. (Nasdaq:OMPI), today announced first
quarter 2009 financial results will be released after the market closes
on Thursday, May 7, and will be followed by an investor conference call
at 4:15 p.m. Eastern time (1:15 p.m. Pacific time).
Investors interested in participating in the live call can dial (888)
549-7750 from the U.S. International callers can dial (480) 629-9041. A
telephone replay will be available approximately two hours after the
call concludes and will be available through Thursday, May 21, by
dialing (800) 406-7325 from the U.S., or (303) 590-3030 for
international callers and entering confirmation code 4059472.
There also will be a simultaneous webcast available on the Investor
Relations section of the Company's web site at www.obagi.com.
For those unable to participate during the live broadcast, the webcast
will be archived for 30 days.
About Obagi Medical Products, Inc.
Obagi Medical Products develops and commercializes skin health products
for the dermatology, plastic surgery, and related aesthetic markets.
Using its Penetrating Therapeutics™ technologies, Obagi Medical's
products are designed to improve penetration of agents across the skin
barrier for common and visible skin conditions in adult skin including
chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The
history of Obagi's skin care product introductions is as follows: Obagi
Nu-Derm®, 1988; Obagi-C® Rx (the first and only prescription-strength
vitamin C and hydroquinone system), 2004; Obagi® Professional-C (a line
of highly stable vitamin C serums), 2005; Obagi® Condition and Enhance
for use with cosmetic procedures to enhance patient outcomes and
satisfaction, 2006; Obagi ELASTIderm™ eye treatment and Obagi
CLENZIderm® M.D. acne therapeutic systems, 2007; a formulation of Obagi
CLENZIderm® M.D. Systems for normal to dry skin, June 2007; Obagi
ELASTIderm™ Décolletage System, January 2008; SoluCLENZ Rx Gel for acne
treatment in the pharmacy channel in August 2008; and the Obagi®
Rosaclear™ System for Rosacea in January 2009. Visit www.obagi.com
for more information.
Obagi Medical Products, Inc.
Preston Romm
CFO, EVP of
Finance, Operations and Administration
(562) 628-1007
or
Investors:
ICR,
Inc.
Ina McGuinness or Lena Adams
(310) 954-1100
